OARS funding Cancer

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

ISN/CTR seeks to build self-sufficient nuclear, biological, and chemical security with partner governments. Since 2012, ISN/CTR has funded the development of an evaluation tool to annually measure the effectiveness of its ISN/CTR programming. The ISN/CTR metrics tool is designed to assess the human element of threat reduction as evidenced by the establishment of nuclear, biological, and chemical security cultures in partner countries, institutions, and individuals. For the current NOFO, ISN/CTR is seeking a new analysis of program work beyond 2017 using this evaluation tool for programming that occurred in ISN/CTR partner countries.

Miami University researchers can provide input about the professional development opportunities they'd like to see OARS offer in the next year by completing this 5-minute survey.

LUNGevity's Career Development Awards for Translational Research program was created to support future research leaders who will keep the field of lung cancer research vibrant with new ideas. Applicants must be within the first five years of their faculty appointment. The Career Development Awards are mentored awards; a mentoring plan is part of the required submission. Projects that will be funded in 2018 are expected to have a direct impact on the early detection of lung cancer or on the outcomes of lung cancer, or to provide a clear conceptual or experimental foundation for the future development of methods for early detection and/or individualized treatment, including through targeted therapy and immunotherapy. Career Development Awards may be for a maximum of $300,000: $100,000 per year for 3 years

The PFD Research Foundation together with the June Allyson Foundation has awarded over $1.5 million in grants to AUGS members since 1998. The Foundation serves the medical profession by supporting promising, innovative research regarding the causes, prevention, cure and treatment of pelvic floor disorders. Foundation research funds are made available to qualified AUGS members to pursue their research question. Goals of this research grant program are to support the completion of research projects which will lead to publication and presentation at future AUGS Annual Scientific Meetings and to support the development of researchers in the field who will go on to obtain additional funding for future research on pelvic floor disorders. Applicants can submit proposals for the following research awards: PFD Research Foundation Fellow Research Award: A two-year grant awarded to a fellow for clinical/patient-oriented, educational, or lab-based/basic science research. PFD Research Foundation Faculty Research Award: A two-year grant awarded to a junior faculty or affiliate member for clinical/patient-oriented, educational, or lab-based/basic science research. June Allyson Memorial Fund Research Award: A two-year grant awarded to a fellow for lab-based/basic science research. PFD Research Foundation and ICA IC/PBS Research Grant: A one-year grant awarded to a fellow, junior faculty or affiliate member of AUGS and ICA for research related to interstitial cystitis.

The aim of the 2018 Bladder Cancer Research Innovation Award is to support exceptionally novel and creative projects with great potential to produce breakthroughs in our understanding or the management of bladder cancer. The proposed research may be basic, translational, or clinical but must have direct applicability and relevance to bladder cancer and address one of the questions of interest (see below). Proposals for innovative projects that will develop preliminary data necessary to prepare and submit a competitive research grant application to a major funding agency are encouraged. The award is available to full time, independent investigators who are affiliated with a non-profit academic, medical or research institution within the United States or Canada. Candidates not currently performing bladder cancer research are encouraged to apply. Proposals that involve a multidisciplinary approach and/or multi-institutional collaboration are encouraged. The award is for $300,000 over two years ($150,000 per year) for direct research expenses, which may include salary and benefits for postdoctoral or clinical research fellows, and/or research assistants; research/lab supplies; and equipment. The second year of funding is dependent on approval after a one year progress report has been submitted and reviewed by BCAN.

Centers for Disease Control and Prevention (CDC) supports a variety of activities in health departments and organizations aimed at preventing and controlling cancer, the second leading cause of death in US men and women. Since the passage of the Cancer Registries Amendment Act in 1992, the National Program of Cancer Registries (NPCR) has collected data on cancer occurrence, extent, treatment and outcomes in over 45 states and jurisdictions, representing 96% of the US population. CDC's Division of Cancer Prevention and Control (DCPC) has supported successful partnerships with national organizations to define standardized practices in U.S. cancer surveillance and assure and complete, timely, and high-quality data for the official federal U.S. Cancer Statistics. The purpose of this funding opportunity is to build strong partnerships among national organizations involved directly in cancer surveillance in order to enhance the data quality and operational efficiency of CDC’s National Program of Cancer Registries (NPCR). This program has three essential components: 1) Education, Translation and Quality Control of cancer surveillance standards and best practices; 2) Cancer Staging Collaboration and Support; and 3) Standardization and Support for Laboratory and Biomarker Electronic Reporting. The overarching goal of this project is to collaboratively define and promote uniform standards in cancer staging, collection and reporting. Funded entities will identify specific enhancement needs of cancer registries and support cancer surveillance professionals, including reporters (e.g. facilities, labs), tumor registrars, and registries to submit high quality, standardized data via central cancer registries to NPCR. Relevant performance measures will be used to assess the recipients’ activities that enhance the standards, quality, and operations of NPCR cancer surveillance system.

This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as "chemobrain." A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.

The purpose of the Funding Opportunity Announcement (FOA) is to support pilot research projects using a "Traceback" approach to genetic testing women with a personal or family history of ovarian cancer and reaching out to family members to identify unaffected individuals at increased risk for cancer in different clinical contexts and communities, including racially/ethnically diverse populations.

The purpose of the Funding Opportunity Announcement (FOA) is to support research projects using a Traceback approach to genetic testing to identify unaffected individuals at increased risk for cancer in different clinical contexts and communities, including racially/ethnically diverse populations.

The EIAs provide funding of up to $100,000 per year for two years to established melanoma researchers, or senior researchers working in closely related fields who wish to move into melanoma research All proposals will undergo a rigorous peer-reviewed process by hand-selected experts in diverse areas of melanoma research. Reviewers include members of the MRF's Scientific Advisory Committee (SAC) and the Breakthrough consortium (MRFBC) as well as members of the scientific and clinical melanoma community who are not in conflict with the application. Proposals receiving discrepant scores will be subjected to an interim review. Applications with the highest scores (including those that received a high score in the interim review) are then assessed by a panel of representatives from the initial review group. The top ranked grants are recommended for funding to the MRF's Board of Directors, who will determine the number of grants awarded based on available funds.

The aim of the CDA is to support the next generation of researchers and to significantly improve outcomes and quality of life for prostate cancer patients. The award will provide up to $75,000 per year for three years to be combined with matching funds or in kind contribution from the applicant's institution. Neither ASTRO nor PCF will pay indirect costs as part of this award. One award will be funded. Research must be focused on understanding or treatment of prostate cancer and include use or impact of radiation treatment.

The aim of the CDA is to support the next generation of researchers and to significantly improve outcomes and quality of life for breast cancer patients. The award will provide up to $100,000 per year for two years to be combined with matching funds or in kind contribution from the applicant's institution. Neither ASTRO nor BCRF will pay indirect costs as part of this award. One award will be funded. Research must be focused on understanding or treatment of breast cancer and include use or impact of radiation treatment.

This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as chemobrain. A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.

This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as chemobrain. A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.

This Funding Opportunity Announcement (FOA) is to encourage Research Project Grant (R01) applications to pursue clinical observational (CO) studies to obtain data necessary for designing clinical studies for musculoskeletal, rheumatic, or skin diseases or conditions. A future clinical study may include a clinical trial or an observational study. Research data from observational studies supported by this FOA can enhance clinical study design by providing essential information about disease symptoms, stages and timing of disease progression, comorbid conditions, availability of potential research participants, and outcomes that are important to patients. They also can facilitate efforts to develop and/or validate objective biomarkers or subjective outcome measures for use in a future clinical study. Applicants to this FOA are encouraged to propose studies that address significant obstacles or questions in the design of a clinical project, such as determining the appropriate primary or secondary outcome measures, or identifying the stages of disease during which patients are most likely to respond to an intervention. Only observational studies will be supported through this FOA.

The “Partner Actions to Improve Oral Health” program is a five-year competitive renewal to continue CDC investment in and support of oral health promotion and disease prevention programs. The purpose is to build the strength and effectiveness of state oral health programs recipients to prevent and control oral diseases and related conditions. Under component 1, recipient will work with all NOFO DP18-1810 funded programs to provide technical assistance, training, and capacity building resources for: 1) the Basic Screening Survey, 2) evidence-based oral health strategies (i.e., school sealant programs and community water fluoridation) and infection prevention and control practices, 3) oral health surveillance, 4) evaluation of oral health programs, and 5) reports on the oral health program capacity for all 50 states (CDC-funded and non-funded states). Under component 2, recipient will work with six programs selected NOFO DP18-1810 to integrate oral health with other chronic disease programs (i.e., medical/dental integration). Recipient will provide technical assistance for medical/dental integration programs, and compile examples of effective medical/dental integration programs and strategies. The proposed program will replace and build upon FOA 13-1313 [FY2013-FY2018]. Successful implementation and execution of the NOFO strategies will result in decreases in dental caries, oral health disparities, and co-morbid chronic diseases.

As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to use submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects.

The foundation encourages grant applications for short-term (one year) support of new cancer researchers or new approaches by established cancer researchers. It is anticipated that this early stage funding may lead to subsequent and expanded support from government agencies.